Enigma Diagnostics, a Porton Down, Salisbury, UK-based provider of molecular diagnostic point-of-care infectious disease testing, raised $50m in funding.
Chinese private equity fund Shanghai Debay Capital made the investment.
The funding will be deployed over 18 months to support global commercialization of the Enigma® ML system following its CE marking in early 2014.
Led by John McKinley, Chairman, Enigma Diagnostics is a global leader in Point-of-Care infectious disease testing. Leveraging its proprietary technologies and Intellectual Property, the company has developed the Enigma® Mini Laboratory (ML) system, combining real-time PCR (polymerase chain reaction) with both laboratory and decentralised Point-of-Care testing for a wide range of DNA and RNA disease targets.
FinSMEs
22/10/2014